Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 411,682
  • Shares Outstanding, K 43,796
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,480 K
  • EBIT $ -172 M
  • EBITDA $ -169 M
  • 60-Month Beta 3.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 139.15% (+10.41%)
  • Historical Volatility 162.98%
  • IV Percentile 21%
  • IV Rank 9.74%
  • IV High 1,176.69% on 03/20/25
  • IV Low 27.16% on 04/14/25
  • Expected Move (DTE 20) 1.73 (18.36%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 333
  • Volume Avg (30-Day) 1,006
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 6,422
  • Open Int (30-Day) 5,058
  • Expected Range 7.67 to 11.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 5
  • High Estimate -0.81
  • Low Estimate -0.88
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.45 +45.74%
on 12/02/25
13.67 -31.24%
on 12/15/25
+1.72 (+22.40%)
since 11/26/25
3-Month
5.30 +77.36%
on 10/07/25
13.67 -31.24%
on 12/15/25
+3.30 (+54.10%)
since 09/26/25
52-Week
1.78 +428.09%
on 04/17/25
13.67 -31.24%
on 12/15/25
+5.42 (+136.18%)
since 12/26/24

Most Recent Stories

More News
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  Miv-cel...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune...

KYTX : 9.40 (+4.56%)
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential

These two biotech disruptors are poised for triple-digit breakout gains.

KYTX : 9.40 (+4.56%)
JANX : 14.25 (-0.42%)
$SPX : 6,929.94 (-0.03%)
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Initial funding of $25 million from the first of four tranches  Facility strengthens Kyverna’s financial flexibility, further supporting advancement of its late-stage indications in generalized...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically...

KYTX : 9.40 (+4.56%)
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate...

KYTX : 9.40 (+4.56%)

Business Summary

Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 10.39
2nd Resistance Point 9.91
1st Resistance Point 9.66
Last Price 9.40
1st Support Level 8.93
2nd Support Level 8.45
3rd Support Level 8.20

See More

52-Week High 13.67
Last Price 9.40
Fibonacci 61.8% 9.13
Fibonacci 50% 7.72
Fibonacci 38.2% 6.32
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar